RxDoctor Payments Data

Lindsey Adams, NP

Nurse Practitioner · Fenton, MONPI 1326611757

Payments from drug & device makers

$3,097in general payments, 2019–2025

Across 16 payments — averaging $193.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Hollister Incorporated$2K
  • Convatec Inc.$137
  • Medtronic$134
  • Progenics Pharmaceuticals, Inc.$125
  • 180 Medical, Inc.$113
  • Novo Nordisk$111
  • plus $72 from 2 others

What the payments were for

  • Speaking & faculty fees$2,25073%
  • Travel & lodging$843%
  • Food & beverage$76325%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Hollister Incorporated5$2,405
Convatec Inc.4$137
Medtronic1$134
Progenics Pharmaceuticals, Inc.1$125
180 Medical, Inc.2$113
Novo Nordisk1$111
Astellas Pharma US Inc1$51
ABC Home Medical Supply, Inc.1$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,097 in reported general payments places this provider in the 85th percentile of 1,898 nurse practitioner providers in Missouri.

See all nurse practitioner providers in Missouri

Medicare billing

Part B allowed, 2024
$38,652
Medicare patients
219
Services billed
915

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron107$91,228
GemtesaVibegron61$40,430
Estradiol113$13,076
Potassium Citrate ErPotassium Citrate41$6,851
Tamsulosin Hcl429$6,241
Solifenacin Succinate49$4,087
Trimethoprim41$2,577
YuvafemEstradiol12$2,541
Fosfomycin Tromethamine12$1,485
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst73$1,104
Methenamine Hippurate20$957
Oxybutynin Chloride ErOxybutynin Chloride40$860
Cephalexin38$834
Finasteride74$789
Testosterone Cypionate18$733

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$51$91,228107 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,898 nurse practitioner providers in Missouri.

Other nurse practitioner in Fenton

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →